文献速递系统性红斑狼疮其他结缔组织病

ANA相关关节炎:面向篮式试验人群的临床与生物标志物特征分析

ANA-associated arthritis: clinical and biomarker characterization of a population for basket trials.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

该观察性研究纳入294例ANA相关风湿与骨骼肌肉疾病患者,其中213例存在炎症性骨骼肌肉症状;作者提出ANA相关关节炎这一跨诊断人群,并通过高斯混合模型聚出高、低骨骼肌肉疾病活动两个聚类;高活动聚类包含全部活动性关节肿胀患者且泼尼松龙使用、医生总体评估及干扰素相关标志物更高。

要点

  • ANA相关RMD中炎症性骨骼肌肉症状见于213/294例患者。
  • 各诊断间多数变量无差异,EQ5D-5L指数与活动域在MCTD/pSS较低(均P<0.05)。
  • 高骨骼肌肉疾病活动聚类(n=89)包含全部活动性关节肿胀患者,泼尼松龙使用与PGA更高。

核心结论

  • 作者定义了ANA相关关节炎,认为其是较现有RMD人群在临床试验中更临床与免疫同质、在临床中治疗适用更广泛的人群。

研究设计与样本

  • 观察性研究,纳入ANA相关风湿与骨骼肌肉疾病患者,分析人口学变量、合并症、治疗、疾病活动工具(BILAG、SLEDAI、ESSDAI、医生VAS)、患者报告结局(SF36、FACIT-Fatigue、EQ5D、ICECAP-A、WPAI、患者VAS)及生物标志物谱(六基因表达评分、流式细胞术、自身抗体谱),并采用高斯混合模型(GMM)重新聚类。

主要发现

  • 炎症性骨骼肌肉症状在ANA相关RMD中普遍存在,见于213/294例患者。
  • 在ANA相关关节炎患者中,除EQ5D-5L指数与活动域在MCTD/pSS较低(均P<0.05)外,多数变量在各诊断间无差异。
  • 纤维肌痛与骨关节炎患病率在各诊断间相似,治疗使用差异显著,生物制剂使用在SLE最多(P<0.05)。
  • GMM得到两个跨疾病聚类:高骨骼肌肉疾病活动(n=89)与低骨骼肌肉疾病活动(n=124)。
  • 高骨骼肌肉疾病活动聚类包含全部活动性关节肿胀患者,且泼尼松龙使用、医生总体评估(PGA)、Sm/RNP/SmRNP/chromatin阳性、Tetherin平均荧光强度(MFI)及IFN Score-A活性显著更高,纤维肌痛与骨关节炎患病率数值上更低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: ANA-associated rheumatic and musculoskeletal (MSK) diseases (RMDs) [SLE, primary SS (pSS), scleroderma, inflammatory myositis, MCTD and UCTD] make up a disease spectrum with overlapping clinical and immunological features. MSK inflammation is common and impactful across ANA-associated RMDs. The objectives of this study were to evaluate MSK inflammation (ANA-associated arthritis) prevalence in a multidisease ANA-associated RMD study, assess its clinical impact across ANA-associated RMD diagnoses, propose new basket groupings of patients, and evaluate immunological profiles in legacy and new basket contexts. METHODS: An observational study enrolled patients with ANA-associated RMDs. Demographic variables, comorbidities, therapies, disease activity instruments [BILAG, SLEDAI, the EULAR SS disease activity index (ESSDAI), physician visual analogue scale (VAS)], patient-reported outcomes [SF36, FACIT-Fatigue, EQ5D, ICECAP-A, Work Productivity and Activity impairment (WPAI), patient VAS] and the biomarker profile (six-gene expression scores, flow cytometry, autoantibody profile) were analysed. Reclustering utilized Gaussian mixture modelling (GMM). The clinical and immune features of new and legacy clusters were compared. RESULTS: Inflammatory MSK symptoms were prevalent across ANA-associated RMDs, in 213/294 patients. In ANA-associated arthritis patients, most variables did not differ between diagnoses, with the exception of the EQ5D-5L index and mobility domains (lower in MCTD/pSS, both P < 0.05). FM and OA prevalence were similar across diagnoses. Therapy use differed significantly, the use of biologics being greatest in SLE (P < 0.05). GMM yielded two multidisease clusters: High MSK disease activity (n = 89) and low MSK disease activity (n = 124). The high MSK disease activity cluster included all patients with active joint swelling, and they had significantly higher prednisolone usage, physician global assessment (PGA), Sm/RNP/SmRNP/chromatin positivity, Tetherin mean fluorescence intensity (MFI), and IFN Score-A activity, along with numerically lower FM and OA prevalence. CONCLUSION: We defined ANA-associated arthritis, a more clinically and immunologically homogeneous population than existing RMD populations for trials, and a more prevalent population for therapies in the clinic.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Arnold J, Carter LM, Md Yusof MY, et al. ANA-associated arthritis: clinical and biomarker characterization of a population for basket trials. Rheumatology (Oxford). 2024. PMID: 39087598. doi:10.1093/rheumatology/keae269

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。